This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E85.2 / E85.4 | Special Copayment Reduction: V121 |
| B. Synonyms | Heredofamilial amyloidosis, unspecified (E85.2), organ-limited amyloidosis (E85.4), localized amyloidosis, isolated organ amyloidosis |
| C. Adult onset | High likelihood of first onset in adulthood — most present after age 40, and the organ-limited form also occurs in old age |
| 1. History | Amyloid named by Rudolf Virchow in the 19th century; classification system by precursor protein established in the late 20th century |
| 2. Causes | Various precursor proteins such as AA, AL, ATTR, Aβ2M, and ALect2 deposited in amyloid form in a single or specific organ |
| 3. Genetics | E85.2 includes, besides pathogenic TTR mutations, apolipoprotein (AApoAI, AApoAII, AApoAIV), fibrinogen A alpha, and lysozyme mutations |
| 4. Epidemiology | The organ-limited form has a relatively more benign course than the systemic form; various organs may be involved, such as localized skin, conjunctiva, bladder, and airway |
| 5. Pathophysiology | Overproduction or instability of the precursor protein → local amyloid fibril formation → organ dysfunction |
| 6. Symptoms | Varies with the organ involved: kidney (proteinuria, renal failure), heart (heart failure, arrhythmia), liver (hepatomegaly), skin (papules, macules), airway (dyspnea) |
| 7. Signs | Organ-specific signs: proteinuria/edema (kidney), cardiomegaly/low voltage (heart), hepatomegaly/jaundice (liver), macroglossia (AL type) |
| 8. Screening | Serum and urine protein electrophoresis, free light chains, echocardiography, renal function tests, family history investigation |
| 9. Diagnosis | Tissue biopsy with Congo red staining + laser microdissection mass spectrometry (LMD-MS) to identify the precursor protein |
| 10. Treatment | Treatment of the underlying disease (AA type), chemotherapy and autologous hematopoietic stem cell transplantation (AL type), TTR stabilizers/RNA therapies (ATTR type), local removal for the organ-limited form |
| 11. Prognosis | Varies greatly by type and organ involved; the organ-limited form is generally favorable, poor prognosis with cardiac involvement in the AL type |
| 12. Prevention | Treatment of underlying chronic inflammatory diseases (prevention of the AA type), genetic counseling, family screening (genotype) |
| 13. References | Wechalekar et al. Lancet 2016 and 9 other papers |
The term amyloid was first used in 1853 by the German pathologist Rudolf Virchow when he described an abnormal substance in tissue that stained blue like starch with iodine and sulfuric acid. Later, in 1875, this substance was found to be composed of protein, and throughout the first half of the 20th century, the associations between amyloid deposition and various systemic diseases were gradually elucidated.
In the 1960s, Congo red staining with apple-green birefringence under polarized light microscopy was established as the standard method for diagnosing amyloid, and through the 1970s~1980s the major types of amyloid precursor proteins were identified in turn, including AA (amyloid A protein, reactive amyloidosis), AL (immunoglobulin light chain), and ATTR (transthyretin). The International Society of Amyloidosis (ISA) has proposed a standardized amyloid protein nomenclature since 1993, and in 2020 about 36 human amyloid precursor proteins were included in the official list.
The concept of organ-limited amyloidosis became established when the group in which amyloid deposition is confined to a single organ or local tissue, unlike the systemic form, was classified separately. ICD-10 distinguishes E85.2 (heredofamilial amyloidosis, unspecified) for cases in which the genetic cause has not been clearly identified or a specific code is difficult to assign among several gene mutations, and E85.4 (organ-limited amyloidosis) for cases in which deposition is confined to a single organ.
Amyloidosis is not a single disease but a group of diseases arising when any of more than 40 amyloid precursor proteins forms amyloid fibrils and deposits in tissue. The conditions corresponding to E85.2 (heredofamilial amyloidosis, unspecified) and E85.4 (organ-limited amyloidosis) encompass cases among these various types that are not classified under a specific code.
Causative genes that may fall into the heredofamilial amyloidosis (E85.2) category include mutations in apolipoprotein A-I (APOA1), apolipoprotein A-II (APOA2), apolipoprotein A-IV (APOA4), fibrinogen alpha chain (FGA), lysozyme (LYZ), gelsolin (GSN), and cystatin C (CST3), each showing its own clinical phenotype and organ involvement. TTR mutations not clearly classified as the neuropathic form (E85.1), or with other phenotypes such as the cardiac form, may also be classified as E85.2.
Organ-limited amyloidosis (E85.4) refers to cases in which amyloid does not spread systemically but is deposited only in a specific organ; deposition in the bladder, airway, ocular conjunctiva, skin, breast, and so on by AL protein produced by local plasma cells is typical. In these cases, unlike systemic plasma cell proliferative disorders (multiple myeloma, systemic AL amyloidosis), serum monoclonal protein is often absent or minimal. Cutaneous amyloidosis also includes cases due to AL31/ALam protein derived from keratinocytes (macular amyloidosis, lichen amyloidosis).
Various gene mutations are involved in heredofamilial amyloidosis, unspecified (E85.2), and most are inherited in an autosomal dominant manner. The features of the main genes are as follows.
AApoAI (amyloid precursor protein: apolipoprotein A-I, APOA1 gene): autosomal dominant, involvement of kidney, liver, heart, and peripheral nerves. Mutations such as Arg26, Glu34, Asp76, and Leu90 have been reported. AApoAII (APOA2 gene): autosomal dominant, the renal form is typical, causing nephrotic syndrome and renal failure. AApoAIV (APOA4 gene): autosomal dominant, late onset, mainly kidney and heart involvement. Fibrinogen amyloidosis (AFib, FGA gene): mutations such as Glu526Val, autosomal dominant, isolated renal involvement is characteristic, progressing to renal failure. Lysozyme amyloidosis (ALys, LYZ gene): Ile56Thr, Asp67His mutations, autosomal dominant, reported in certain British families, involvement of liver, kidney, and gastrointestinal tract. Gelsolin amyloidosis (AGel, GSN gene): Asp187Asn/Tyr mutations, also called Finnish type amyloidosis, corneal dystrophy, cranial nerve palsy, peripheral neuropathy. Cystatin C amyloidosis (ACys, CST3 gene): Icelandic type, causing cerebral hemorrhage through cerebral amyloid angiopathy.
Organ-limited amyloidosis (E85.4) is mostly sporadic, and cases with a clearly identified genetic predisposition are rare. Production of AL light chains by local plasma cells is the main mechanism, and familial clustering is rare.
The overall incidence of systemic amyloidosis is estimated at about 10 per million population. Of these, AL amyloidosis is the most common (annual incidence in Western countries about 10 per million), and AA amyloidosis varies greatly by region depending on the prevalence of chronic inflammatory diseases. Heredofamilial amyloidosis (E85.2 category) is rare, with tens to hundreds of patients of each subtype scattered around the world.
Accurate epidemiological data on organ-limited amyloidosis (E85.4) are lacking, but among these, urinary tract (bladder, ureter) amyloidosis, airway (larynx, bronchi) amyloidosis, and ocular conjunctival amyloidosis are the most frequently diagnosed clinically. Cutaneous amyloidosis has a relatively high prevalence in Asian countries (particularly China, Taiwan, Thailand, Korea, and Japan), and macular amyloidosis and lichen amyloidosis are the main forms. Cutaneous amyloidosis is associated with chronic pruritus, and deposition of fibrillar amyloid (AKer) is characteristic.
AFib amyloidosis is well known to recur after kidney transplantation, so the importance of pre-transplant genetic testing is emphasized. AGel (gelsolin) amyloidosis has a particularly high prevalence in Finland. Sex distribution differs by subtype, but most present in adulthood.
The common mechanism of amyloid fibril formation stems from structural instability or overproduction of the precursor protein. When a protein that normally folds and remains soluble shifts to a partially unfolded or misfolded state because of mutation, post-translational modification, overproduction, or other reasons, insoluble fibrils form through intermolecular beta-sheet interactions.
In heredofamilial subtypes, specific amino acid substitutions reduce protein solubility and stability. For example, the Glu526Val mutation of the fibrinogen alpha chain destabilizes the C-terminal structure of the fibrinogen molecule, causing amyloid to deposit selectively in the renal glomeruli. Gelsolin mutations alter interactions with the extracellular matrix, causing amyloid deposition in peripheral nerves and the cornea.
In organ-limited amyloidosis, precursor protein overproduced by local cells (plasma cells, keratinocytes) within a specific tissue does not spread into the systemic circulation and forms amyloid only within that organ. AL light chain amyloid deposition by local plasma cells is typical, and the local cytokine environment and extracellular matrix components (heparan sulfate proteoglycans, serum amyloid P component, apolipoprotein E) act as cofactors promoting deposition. Amyloid fibrils themselves and their oligomeric precursors cause organ dysfunction through direct cytotoxicity, cell membrane disruption, and activation of inflammatory responses.
Symptoms vary greatly depending on the type of organ in which amyloid is deposited and the extent of deposition, and heredofamilial amyloidosis, unspecified (E85.2) and organ-limited amyloidosis (E85.4) each have characteristic features.
Renal involvement (mainly AFib, AApoAI, AApoAII) begins with proteinuria (particularly with glomerular deposition) and, as it progresses, can lead to nephrotic syndrome and chronic renal failure. Hepatic involvement presents as hepatomegaly, elevated alkaline phosphatase (ALP), portal hypertension, and coagulation abnormalities. Cutaneous amyloidosis (organ-limited form) is characterized by brown papules or macular pigmentation on the back and lower limbs, accompanied by severe pruritus. Airway amyloidosis causes hoarseness (laryngeal involvement), chronic cough, dyspnea, recurrent pneumonia, and so on.
In bladder amyloidosis (organ-limited form), painless hematuria is the most common symptom, and reduced bladder capacity, urinary frequency, and urgency may be present. Ocular conjunctival amyloidosis presents as a painless yellow conjunctival mass and recurrent bleeding. Gelsolin amyloidosis (AGel) is characterized by corneal lattice dystrophy, facial nerve palsy (skin sagging), cutis laxa, and peripheral neuropathy. In cystatin C amyloidosis, recurrent cerebral hemorrhage in young adulthood (20s~30s) is the main symptom.
Physical examination and test findings differ depending on the organ involved. With renal involvement, proteinuria (nephrotic syndrome if >3.5 g/day), lower limb edema, hypertension, and elevated serum creatinine are observed. With hepatic involvement, hepatomegaly (liver palpable beyond the costal margin), jaundice, ascites, and coagulation abnormalities (prolonged PT, hypoalbuminemia) appear. With cardiac involvement, left ventricular hypertrophy, low voltage on ECG, arrhythmias, and elevated BNP/NT-proBNP are found.
In the systemic AL form, macroglossia is a pathologically specific sign: amyloid deposition in the tongue causes it to enlarge, with tooth indentations along its lateral margins. In cutaneous amyloidosis (organ-limited form), characteristic papular pigmented lesions on the upper arms or lower legs with a bilaterally symmetric distribution are observed. In gelsolin amyloidosis, slit-lamp examination of the cornea reveals lattice dystrophy and reduced corneal sensation.
In airway amyloidosis, yellowish-white submucosal nodules are observed on laryngoscopy or bronchoscopy. In bladder amyloidosis, yellowish deposits with submucosal vascular dilation are seen on cystoscopy. An abnormal serum free light chain (kappa/lambda) ratio and a positive serum monoclonal protein (M-protein) suggest the systemic AL form, but these may be absent or minimal in the organ-limited form.
When amyloidosis is suspected, basic tests for classifying the amyloid type are performed first. Serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (IFE), and serum free light chain (FLC) measurement are essential tests for excluding the AL type. Urine protein electrophoresis (UPEP), 24-hour urine protein quantification, and urine immunofixation electrophoresis are also included in the basic workup.
Measurement of serum amyloid A (SAA) protein is useful for screening for AA amyloidosis, and investigation of chronic inflammatory diseases that drive SAA (rheumatoid arthritis, familial Mediterranean fever, inflammatory bowel disease, chronic infections, etc.) is needed. Renal function tests (glomerular filtration rate, serum creatinine, proteinuria quantification), liver function tests (ALP, ALT, AST, albumin), cardiac markers (BNP/NT-proBNP, troponin), ECG, and echocardiography are performed to assess organ involvement.
When heredofamilial amyloidosis (E85.2) is suspected, gene panel testing (amyloidosis panel NGS including TTR, APOA1, FGA, LYZ, GSN, CST3, APOA2, APOA4, etc.) is considered after investigating the family history. When cutaneous amyloidosis is suspected, skin biopsy is the most direct screening and diagnostic method.
Amyloidosis is confirmed by demonstrating amyloid deposition on tissue biopsy. The standard diagnostic sequence consists of three steps: confirming the presence of amyloid in tissue → identifying the type of amyloid precursor protein → genetic testing (when a hereditary type is suspected).
The presence of amyloid is confirmed by apple-green birefringence under polarized light microscopy after Congo red staining. Thioflavin T fluorescent staining is more sensitive but less specific and is therefore used as an adjunct. The most accurate method for identifying the precursor protein type is mass spectrometry combined with laser microdissection (LMD-MS), which can distinguish various amyloid types simultaneously in a single biopsy specimen. Immunohistochemical (IHC) staining is performed for TTR, AA, kappa/lambda light chains, ALys, AFib, and others, but false negatives/false positives are possible depending on antibody specificity, so combination with LMD-MS is recommended.
Abdominal fat pad aspiration (AFPA) is the least invasive biopsy method, with a sensitivity of 60~80%, and rectal, renal, liver, and endomyocardial biopsies are performed when confirming involvement of each organ. To confirm the genotype, Sanger sequencing of the relevant genes, such as APOA1, FGA, LYZ, and GSN, or an NGS panel is performed. For cutaneous amyloidosis, a 4mm punch biopsy is sufficient, and Congo red staining is added along with PAS staining.
The principles of treatment are to reduce production of the amyloid precursor protein or treat the underlying disease, combined with preservation of the function of involved organs and symptomatic treatment.
The key to treatment is aggressive treatment of the underlying chronic inflammatory disease to normalize serum amyloid A protein (SAA) levels. In rheumatoid arthritis, biologic agents (anti-TNF, tocilizumab, etc.) effectively suppress SAA. In familial Mediterranean fever, colchicine is the standard treatment for preventing attacks and halting the progression of AA amyloidosis.
Local treatment is the main approach. For airway (laryngeal, bronchial) amyloidosis, bronchoscopic laser removal, CO2 laser excision, and radiation therapy are used. For bladder amyloidosis, cystoscopic transurethral resection (TURB) or electrocautery is effective for controlling hematuria. For cutaneous amyloidosis, topical steroids, topical capsaicin, topical tacrolimus, retinoids, and DMSO (dimethyl sulfoxide) application are used to relieve pruritus, but they do not remove the amyloid deposits themselves. For ocular conjunctival amyloidosis, conjunctival excision may be performed.
In AFib amyloidosis with progressive renal failure, kidney transplantation is performed, but because recurrence after transplantation is frequent, combined liver-kidney transplantation is more effective in preventing recurrence. Heart transplantation is considered for cardiac involvement in AApoAI, and kidney transplantation for renal involvement in AApoAI. Most RNA therapies or stabilizers specific to each genotype are still in clinical development, and treatment corresponding to the TTR type is applied to the ATTR phenotype.
Prognosis varies greatly depending on the amyloid type, the organs involved, and the extent of organ damage at diagnosis. Organ-limited amyloidosis (E85.4) generally has a better prognosis than the systemic form, and bladder amyloidosis often shows a long, stable course after appropriate local treatment. However, airway amyloidosis can have a poor long-term prognosis due to respiratory failure from airway obstruction and recurrent infections.
Cutaneous amyloidosis is not life-threatening but reduces quality of life through chronic pruritus. AFib amyloidosis often progresses to end-stage renal failure without kidney transplantation, and repeat transplantation may be needed because of recurrence after transplantation. AApoAI amyloidosis has a poor prognosis when it simultaneously involves the kidney, liver, and heart. Gelsolin (AGel) amyloidosis progresses slowly over decades, and survival into old age is possible, but dysphagia and respiratory impairment due to cranial nerve palsy can be end-stage complications.
Overall, early diagnosis, assessment of the extent of organ damage, and initiation of treatment of the cause are key to improving prognosis. Regular monitoring of renal, cardiac, and liver function is essential for tracking progression in involved organs.
Prevention of AA amyloidosis lies in early treatment of the underlying chronic inflammatory disease and sustained minimization of serum amyloid A protein (SAA) levels. Aggressive treatment of rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, and similar conditions significantly reduces the risk of developing AA amyloidosis. In patients with familial Mediterranean fever, regular colchicine intake is established as an effective strategy for preventing amyloidosis.
To prevent heredofamilial amyloidosis (E85.2), cascade genetic testing and genetic counseling for the families of confirmed patients are recommended. When a family member is found to carry the same gene mutation, a regular follow-up testing plan according to the organs at risk is established, and presymptomatic baseline renal, cardiac, and neurological function is documented to detect progression early. Preimplantation genetic testing (PGT) can be offered to carrier couples planning to have children.
Organ-limited amyloidosis is mostly sporadic, so direct prevention is difficult. However, in cutaneous amyloidosis, chronic pruritus and skin friction are known aggravating factors, so skin moisturizing care and treatment of pruritus play a supplementary preventive role. Appropriate education of medical staff and establishing a referral system to specialized centers for suspected rare disease cases contribute to indirect prevention by reducing diagnostic delay.